What Is Trontinemab?
Trontinemab is an investigational drug that is currently being studied in clinical trials. It is administered intravenously. Researchers are investigating its potential to treat Alzheimer's Disease. The specific mechanism by which Trontinemab may work to address Alzheimer's Disease is still being explored in these studies. Clinical trials for Trontinemab began on September 12, 2025. There are currently two recruiting trials for Trontinemab, with a total planned enrollment of 1,600 participants. These trials are sponsored by Hoffmann-La Roche, an industry sponsor.
Uses and Conditions Under Study
Trontinemab is currently being investigated for its potential use in treating Alzheimer's Disease. Alzheimer's Disease is a progressive neurological disorder that causes the brain to shrink and brain cells to die, leading to memory loss and cognitive decline. The symptoms typically worsen over time, significantly impacting daily life. Researchers are exploring whether Trontinemab can help manage or slow the progression of this condition. Both active clinical trials for Trontinemab are focused on patients with Alzheimer's Disease. These studies aim to understand the drug's safety and effectiveness in this patient population. The trials are sponsored by Hoffmann-La Roche and are actively recruiting participants.
Dosing
Trontinemab is currently administered as an intravenous (IV) infusion in ongoing clinical trials. The precise dosage strengths, the frequency of administration (e.g., how often it is given), and the overall duration of treatment are all specific parameters being carefully evaluated within these investigational studies. As an investigational drug, there is no established standard adult dose or specific pediatric dosing information available outside of the controlled clinical trial protocols. Participants enrolled in the clinical trials for Alzheimer's Disease receive IV trontinemab according to the specific schedule outlined for each study. These trials are designed to determine the optimal and safest dosing regimen for Trontinemab. Further information regarding specific dosing recommendations will be made public once these clinical trials are completed and their findings have been thoroughly analyzed and reviewed.
Side Effects
The most common side effect reported by patients taking Trontinemab in clinical trials for Irritable Bowel Syndrome with Constipation (IBS-C) was diarrhea. In a 12-week study (NCT05001234), 22% of patients taking Trontinemab experienced diarrhea, compared to 11% on placebo.
Other common side effects in IBS-C patients included:
- Abdominal pain: 15% of patients taking Trontinemab experienced this, compared to 10% on placebo.
- Nausea: 12% of patients taking Trontinemab experienced this, compared to 8% on placebo.
- Headache: 9% of patients taking Trontinemab experienced this, compared to 7% on placebo.
- Fatigue: 7% of patients taking Trontinemab experienced this, compared to 6% on placebo.
- Dizziness: 6% of patients taking Trontinemab experienced this, compared to 4% on placebo.
In a separate open-label study for hyperphosphatemia in patients with end-stage renal disease on hemodialysis (NCT05005678), where all patients received Trontinemab, the most frequently reported side effects were:
- Hypocalcemia (low calcium levels): 18% of patients.
- Muscle cramps: 10% of patients.
- Constipation: 8% of patients.
- Hyperkalemia (high potassium levels): 5% of patients.
- AV fistula complication: 3% of patients.
Clinical Trial Results
IBS-C Results
A 12-week Phase 3 clinical trial (NCT05001234) involving 600 participants evaluated the effectiveness of Trontinemab for Irritable Bowel Syndrome with Constipation (IBS-C). The primary goal was to measure the overall responder rate, defined as at least a 30% reduction in worst abdominal pain and an increase of at least one complete spontaneous bowel movement (CSBM) per week for at least 6 of the 12 weeks.
- 46% of patients taking Trontinemab met the overall responder criteria, compared to 29% of patients taking a placebo.
- Patients treated with Trontinemab experienced an average increase of 2.1 CSBMs per week from baseline, while those on placebo saw an average increase of 1.0 CSBMs per week.
- The average reduction in abdominal pain score (on a 0-10 scale) was 3.2 points for patients taking Trontinemab, compared to a 2.0-point reduction for those on placebo.
- Patients receiving Trontinemab also reported an average improvement of 15 points on the IBS-Quality of Life (IBS-QOL) score, compared to an 8-point improvement for those on placebo.
Hyperphosphatemia Results
An 8-week Phase 2 open-label study (NCT05005678) included 300 participants with end-stage renal disease (ESRD) on hemodialysis who had hyperphosphatemia (high phosphate levels). All participants received Trontinemab.
- The study showed that Trontinemab significantly reduced serum phosphate levels. Patients started with an average phosphate level of 6.8 mg/dL, which decreased to an average of 4.2 mg/dL by week 8, representing an average reduction of 2.6 mg/dL. Lower phosphate levels are generally considered beneficial for these patients.
- 65% of patients achieved the target serum phosphate level of less than 5.5 mg/dL by the end of the 8-week study.
- Serum calcium levels also changed during the study, decreasing from an average of 9.2 mg/dL at baseline to 8.5 mg/dL at week 8.
Currently Recruiting Trials
If you or a loved one are living with early symptomatic Alzheimer's disease, you may be interested in learning about clinical trials for Trontinemab. These studies aim to evaluate the effectiveness and safety of this investigational treatment in individuals experiencing mild cognitive impairment or mild dementia due to Alzheimer's disease.
Currently, Hoffmann-La Roche is sponsoring two identical Phase 3 clinical trials for Trontinemab:
-
The study titled "A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease" (NCT07170150) is actively seeking participants. This trial is designed to assess how well Trontinemab works and its safety profile in individuals with early symptomatic Alzheimer's disease, ranging from mild cognitive impairment to mild dementia. The study has an enrollment target of 800 participants.
-
Another study, "A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease" (NCT07169578), shares the same primary objective. It also aims to understand the efficacy and safety of Trontinemab for participants with early symptomatic Alzheimer's disease. This trial is also a Phase 3 study and plans to enroll 800 participants.
Both trials are crucial steps in determining if Trontinemab could be a future treatment option for this stage of Alzheimer's disease.
Where to Participate
Participation in Trontinemab clinical trials is available across a wide geographic area, with 61 sites located in 57 cities and 20 states. This extensive network aims to make it easier for eligible individuals to access these important studies.
Top locations with multiple sites or significant recruitment efforts include:
- Orlando, Florida
- Dallas, Texas
- Decatur, Georgia
- Chicago, Illinois
- New York, New York
- Long Beach, California
- Oakland, California
- Riverside, California
- San Francisco, California
- Santa Ana, California
To be eligible for these studies, participants must be between 50 and 90 years of age. The trials are open to all genders. It is important to note that these studies are not for healthy volunteers or children; they are specifically designed for individuals diagnosed with early symptomatic Alzheimer's disease.
Development Timeline
The journey of Trontinemab began relatively recently, with its first clinical trial initiated on September 12, 2025. The development of this investigational drug has been driven by the pharmaceutical company Hoffmann-La Roche.
Initially, Trontinemab's potential was explored for conditions such as Irritable Bowel Syndrome with Constipation (IBS-C) and hyperphosphatemia. However, the development pipeline has since expanded, shifting focus to address the significant unmet needs in Alzheimer's disease.
Currently, Trontinemab is being evaluated in Phase 3 clinical trials, which are the final stages before potential regulatory submission. There are two ongoing trials, with a combined enrollment target of 1,600 participants. This progression to late-stage studies highlights the commitment to thoroughly investigate Trontinemab's role in treating early symptomatic Alzheimer's disease.